- Home
- ONEG vs HUMA Comparison
ONEG vs HUMA Comparison
Compare ONEG & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONEG | HUMA |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 182.6M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | ONEG | HUMA |
|---|---|---|
| Price | $2.01 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.13 |
| AVG Volume (30 Days) | 154.8K | ★ 5.2M |
| Earning Date | 01-14-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $52,231,000.00 | $1,571,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $731.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.91 |
| 52 Week High | $13.50 | $4.85 |
Technical Indicators
Market Signals| Indicator | ONEG | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 47.06 |
| Support Level | $1.93 | $0.91 |
| Resistance Level | $2.45 | $1.25 |
| Average True Range (ATR) | 0.26 | 0.08 |
| MACD | 0.18 | 0.01 |
| Stochastic Oscillator | 65.56 | 60.29 |
Price Performance
Historical ComparisonAbout ONEG OneConstruction Group Limited Ordinary Shares
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project includes performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.